Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease

A compound of Formula I

• wherein:
• (i)
• one of R3 and R8 is NHC(O)CH3 and the other is NHC(S)NHCH(CH3)2;
• RA and RB are SO2N(R22)2, or one of RA and RB is SO3R23 and the other is hydrogen or SO3R23, or one of RA and RB is SO3−Y+ and the other is hydrogen, or one of RA and RB is CO2−Y+ and the other is hydrogen or CO2−Y+, or one of RA and RB is P(O)(O−)2(Y+)2 and the other is hydrogen or P(O)(O−)2(Y+)2;
• R2, R4, R5, R6, R7 and R9 are independently hydrogen, halogen, CF3, CN, C(O)R21, CO2R21, CO2−Y+, C(O)N(R22)2, OH, OR21, N(R22)2, N═C═S, NHC(O)R21, NHC(O)OR21, NHC(S)R21, NHC(S)N(R22)2, NHSO2R21, NHSO2N(R22)2, NO2, N2—R22, SOR21, SO2R21, SO3R21, SO3−Y+, OP(O)(OH)2, optionally substituted linear or branched C1-C10 alkyl, optionally substituted linear or branched C2-C10 alkenyl, optionally substituted linear or branched C2-C10 alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• R21 is independently for each occurrence hydrogen, optionally substituted linear or branched C1-C10 alkyl, optionally substituted linear or branched C2-C10 alkenyl, optionally substituted linear or branched C2-C10 alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• R22 is independently for each occurrence hydrogen, optionally substituted linear or branched C1-C10 alkyl, optionally substituted linear or branched C2-C10 alkenyl, optionally substituted linear or branched C2-C10 alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl or C(O)(CH2)nCH3 wherein n=0, 1, 2, 3, 4, 5, or 6, or the two R22 together with the nitrogen they are attached to form an optionally substituted 3-8 membered heterocyclyl;
• R23 is independently for each occurrence optionally substituted linear or branched C1-C10 alkyl, or cyclopropyl;
• Y+ is for each occurrence a cation;
• and
• pharmaceutically acceptable salts thereof;
• or
• (ii)
• R3 and R8 are NHC(O)CH3;
• RA and RB are SO2N(R24)(R25), or one of RA and RB is SO3R23 and the other is hydrogen or SO3R23, or one of RA and RB is SO3−Y+ and the other is hydrogen, or one of RA and RB is CO2−Y+ and the other is hydrogen or CO2−Y+, or one of RA and RB is P(O)(O−)2(Y+)2 and the other is hydrogen or P(O)(O−)2(Y+)2;
• R2, R4, R5, R6, R7 and R9 are independently hydrogen, halogen, CF3, CN, C(O)R21, CO2R21, CO2−Y+, C(O)N(R22)2, OH, OR21, N(R22)2, N═C═S, NHC(O)R21, NHC(O)OR21, NHC(S)R21, NHC(S)N(R22)2, NHSO2R21, NHSO2N(R22)2, NO2, N2—R22, SOR21, SO2R21, SO3R21, SO3−Y+, OP(O)(OH)2, optionally substituted linear or branched C1-C10 alkyl, optionally substituted linear or branched C2-C10 alkenyl, optionally substituted linear or branched C2-C10 alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• R21 is independently for each occurrence hydrogen, optionally substituted linear or branched C1-C10 alkyl, optionally substituted linear or branched C2-C10 alkenyl, optionally substituted linear or branched C2-C10 alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• R22 is independently for each occurrence hydrogen, optionally substituted linear or branched C1-C10 alkyl, optionally substituted linear or branched C2-C10 alkenyl, optionally substituted linear or branched C2-C10 alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted heteroaryl or C(O)(CH2)nCH3 wherein n=0, 1, 2, 3, 4, 5, or 6, or the two R22 together with the nitrogen they are attached to form an optionally substituted 3-8 membered heterocyclyl;
• R23 is independently for each occurrence optionally substituted linear or branched C1-C10 alkyl, or cyclopropyl;
• R24 is independently for each occurrence hydrogen, optionally substituted linear or branched C1-C10 alkyl, optionally substituted linear or branched C2-C10 alkenyl, optionally substituted linear or branched C2-C10 alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted heteroaryl or C(O)(CH2)nCH3 wherein n=0,1,2,3,4,5, or 6;
• R25 is independently for each occurrence hydrogen, or R24 and R25 together with the nitrogen they are attached to form an optionally substituted 3-8 membered heterocyclyl;
• Y+ is for each occurrence a cation;
• and pharmaceutically acceptable salts thereof.